Background: Based on the mechanism of action, combining somatostatin analogues (SSAs) with mTOR inhibitors\nor antiangiogenic agents may provide synergistic effects for the treatment of patients with neuroendocrine\ntumours (NETs). Herein, we investigate the use of these treatment combinations in clinical practice.\nMethods: This retrospective cross-sectional analysis of patients with NETs treated with the SSA lanreotide and targeted\ntherapies at 35 Spanish hospitals evaluated the efficacy and safety of lanreotide treatment combinations in clinical\npractice. The data of 159 treatment combinations with lanreotide in 133 patients was retrospectively collected.\nResults: Of the 133 patients, with a median age of 59.4 (16ââ?¬â??83) years, 70 (52.6 %) patients were male, 64 (48.1 %)\nhad pancreatic NET, 23 (17.3 %) had ECOG PS ?2, 41 (30.8 %) had functioning tumours, 63 (47.7 %) underwent surgery\nof the primary tumour, 45 (33.8 %) had received prior chemotherapy, and 115 (86.5 %) had received prior SSAs.\n115 patients received 1 lanreotide treatment combination and 18 patients received between 2 and 5 combinations.\nLanreotide was mainly administered in combination with everolimus (73 combinations) or sunitinib (61 combinations).\nThe probability of being progression-free was 78.5 % (6 months), 68.6 % (12 months) and 57.0 % (18 months) for\npatients who only received everolimus plus lanreotide (n = 57) and 89.3 % (6 months), 73.0 % (12 months), and 67.4 %\n(18 months) for patients who only received sunitinib and lanreotide (n = 50). In patients who only received everolimus\nplus lanreotide the median time-to-progression from the initiation of lanreotide combination treatment was\n25.8 months (95 % CI, 11.3, 40.3) and it had not yet been reached among the subgroup of patients only receiving\nsunitinib plus lanreotide. The safety profile of the combination treatment was comparable to that of the targeted\nagent alone.\nConclusions: The combination of lanreotide and targeted therapies, mainly everolimus and sunitinib, is widely\nused in clinical practice without unexpected toxicities and suggests efficacy that should be explored in\nrandomized prospective clinical trials.
Loading....